United States

Developed Europe

Developed Rest of World

Emerging Markets

Total Internetional

Revenue by Geography

Revenue segments as reported by the company.

Primary Care

Specialty Care

Oncology

Pfizer CentreOne

Vaccines

Hospital

Internal Medicine

Rare Disease

Inflammation & Immunology

Pfizer Ignite

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, informational and administrative expenses

Research and development expenses

Amortization of intangible assets

Restructuring charges and certain acquisition-related costs

Other (income)/deductions

Acquired in-process research and development expenses

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Pfizer

Sildenafil is a medication used to treat erectile dysfunction and pulmonary arterial hypertension. It is sold as the brand name Viagra among others.

Viagra

Atorvastatin is a member of the medication class known as statins, which are used primarily as a lipid-lowering agent and for prevention of events associated with cardiovascular disease. Like all statins, atorvastatin works by inhibiting HMG-CoA reductase, an enzyme found in liver tissue that plays a key role in production of cholesterol in the body. It is marketed under the trade name Lipitor among others

Lipitor

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Pfizer exceeds $100B in revenue, eyes growth amid challenges

Pfizer's exceptional 2022 performance sets the stage for continued success in 2023.
Strategic investments in R&D and new product launches drive revenue growth expectations.
Challenges include transitioning from emergency status and revenue decline from COVID-related products.
Opportunities lie in increased adoption of combo vaccines and business development goals.

Pfizer reports solid Q1 results, eyes growth through innovation

Pfizer's Q1 performance was strong, driven by revenue growth and patient reach.
The company faces challenges in COVID franchise transition and stock performance.
Strategic acquisitions, new product launches, and market monitoring offer growth opportunities.
Pfizer's focus on innovation, trustworthiness, and commercial efficiency underpin its future success.

Pfizer reports Q2 growth amidst COVID uncertainties and therapeutic optimism

Pfizer's Q2 performance reflects growth in non-COVID revenues, strategic acquisitions, and a focus on new product launches. Challenges include uncertainties in revenue forecasts and operational adjustments post-acquisitions. Opportunities lie in therapeutic advancements and the potential of mRNA flu vaccines.

Pfizer reports strong Q3 performance, eyes growth in non-COVID products

Pfizer's Q3 performance showcased resilience in non-COVID product revenue growth, offsetting COVID-related declines. The company's strategic focus on global health impact and innovative acquisitions positions it for future growth. Challenges in the COVID product segment persist, but Pfizer remains optimistic about opportunities in new product launches and cancer treatment advancements.

Pfizer reports solid 2023 performance, eyes growth and cost savings

Pfizer's 2023 performance was strong despite challenges, with a focus on oncology, R&D, and cost savings. The company aims for revenue growth in 2024, emphasizing shareholder value and strategic priorities.

Pfizer reports robust Q1 earnings, eyes international growth and pipeline

Pfizer's Q1 2024 performance showcased strong revenue figures and strategic focus on non-COVID products and oncology, underlining the company's resilience and growth potential.
While facing challenges in adult market contraction and gross margin issues, Pfizer's strengths in pipeline innovation, product performance, and international market growth position it well for the future.
The company's opportunities lie in continued international expansion, consumer engagement initiatives, and upcoming pipeline advancements, signaling a path for sustained growth and innovation.

Pfizer reports strong Q2 earnings, raises guidance amid leadership changes

Pfizer's Q2 2024 earnings call reflects a robust performance, marked by revenue growth, leadership changes, and enhanced guidance. The company's strategic focus on oncology, vaccines, and product differentiation positions it for continued success. Challenges include maintaining market share post-generics and managing growth expectations for VYNDAQEL.

Pfizer reports robust Q3 earnings, eyes international market growth

Pfizer's Q3 earnings call highlighted strong performance, pipeline advancements, and a focus on shareholder value creation. Challenges include addressing the impact of IRA and maintaining growth in specific product lines. Opportunities lie in international market expansion and continued pipeline innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Nov.  13, 2019  (GLOBE NEWSWIRE) --  CENTOGENE  (Nasdaq: CNTG) ,  a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians and pharmaceutical companies, announced today a new data access and collaboration agreement with Pfizer Inc. (NYSE: PFE). The agreement grants Pfizer access to CENTOGENE’s data repository, which may be used in the discovery and validation of novel genetic and biochemical targets for the potential development of new therapies for rare diseases.

CENTOGENE Signs Data Access and Collaboration Agreement with Pfizer Inc.

Merck

Pfizer (PFE) and Merck KGaA's Bavencio misses the primary goal in a late-stage study evaluating it as the first-line maintenance therapy for patients with metastatic HER2-negative gastric cancer.

Pfizer-Merck KGaA's Bavencio Fails in 2nd Gastric Cancer Study

Merck KGaA MKGAF, -0.36% and Pfizer PFE, -0.91% said Friday that a late-stage clinical trial testing Bavencio as a first-line maintenance treatment for patients with certain forms of gastric cancer failed to meet the study's primary endpoints for survival.

Merck KGaA, Pfizer drug fails to meet endpoints in gastric cancer trial

The pharmaceutical giant and Dow component beat earnings estimates for the 11th consecutive quarter.

Pfizer Beats Earnings as Weekly Chart Stays Positive

Snap

Carvana

Lam Research

Roku

The U.S. stock market’s hottest stocks this year have mostly been youngish companies with little if any profit history. Investors these days are talking conservatively, but investing speculatively.

Snap And 4 Other Large-Caps Up More Than 100 Percent This Year

The U.S. stock market’s hottest stocks this year have mostly been youngish companies with little, if any, profit history.

5 Large-Cap Stocks Are Up More Than 100% This Year

Pfizer's (PFE) CEO Albert Bourla on Q3 2019 Results - Earnings Call Transcript

Apple

General Motors

GrubHub

Shopify

GrubHub, Shopify, Apple, Pfizer and General Motors were our top stock trades from Tuesday. Here's a look at the charts.

5 Top Stock Trades for Wednesday: GM, AAPL, SHOP, GRUB, PFE

The big drugmaker beat Wall Street estimates and weaved a story of stronger future growth.

Pfizer's Q3 Earnings: A Tale of 3 Companies That Investors Should Enjoy

Fitbit

Twitter

Options trading was hot in Fitbit, Pfizer, and Twitter on Monday. Here’s what the data suggests moving forward.

Tuesday’s Vital Data: Fitbit, Pfizer and Twitter

The S&P 500 touched a new record high on Tuesday as investors cheered strong earnings from big drugmakers Merck and Pfizer, while a disappointing profit from Google parent Alphabet kept the Nasdaq firmly in the red.

S&P 500 squeezes higher on robust Merck, Pfizer earnings

The S&P 500 hit a fresh record high on Tuesday, lifted by upbeat earnings from drugmakers Merck and Pfizer, while disappointing quarterly profit from Google-parent Alphabet kept the Nasdaq firmly in the negative territory.

Merck, Pfizer spur S&P 500 to record high; Alphabet weighs on Nasdaq

Merck & Co. Inc. (NYSE: MRK) and Pfizer Inc. (NYSE: PFE) reported their most recent quarterly results before the opening bell Tuesday.

Is This the Turnaround Pfizer and Merck Shareholders Have Been Waiting For?

Pfizer Inc  posted third-quarter profit well above  analysts' estimates on higher sales of cancer drug Ibrance and new heart medicine Vyndaqel, encouraging the largest U.S. drugmaker to lift its earnings forecast for the year.

Pfizer raises 2019 forecast as sales of cancer drug, heart medicine surge

Pfizer (PFE) beats estimates for third-quarter earnings and sales and raises earnings guidance range for 2019 while tightening revenue outlook.

Pfizer (PFE) Rises on Q3 Earnings & Sales Beat, Ups EPS View

Beyond Meat

Alphabet

Mastercard

This morning, after yesterday’s record, investors seem to be in a subdued mood amid mixed earnings reports.

As Earnings Season Rolls On, Alphabet Misses But Others Surprise To Upside

Merck & Co (NYSE: MRK) and Pfizer (NYSE: PFE) both reported a third-quarter earnings beat Tuesday.

Pharma Earnings: Merck, Pfizer Trade Higher On Q3 Beats

Merck and Pfizer earnings easily beat Q3 views Tuesday. Shares of both Dow Jones drug giants rose solidly early Tuesday.

Merck, Pfizer Earnings Beat Views; Dow Jones Drug Giants Rally

Shares of Merck & Co. Inc. MRK, -0.07% and Pfizer Inc. PFE, +1.39% rallied in premarket trading Tuesday after earnings beats, and were the best performers among Dow Jones Industrial Average DJIA, +0.49% components, but not enough to lift the Dow into positive territory.

Merck, Pfizer stock gains on earnings beats would add 23 points to the Dow's price

Pfizer posted a third-quarter profit well ahead of analysts' estimates on higher sales of breast cancer drug Ibrance and raised its earnings forecast for the year, sending the largest U.S. drugmaker's shares up 3%.

Pfizer beats profit estimates, raises 2019 earnings forecast

U.S. drugmaker Pfizer Inc  raised its 2019 full-year earnings forecast on Tuesday, sending its shares up 3%.

Pfizer raises 2019 profit forecast, shares rise

Pfizer Inc. shares PFE, +1.39% rose 3.3% in premarket trade Tuesday, after the drug company beat earnings estimates for the third quarter and raised its profit guidance.

Pfizer shares jump premarket as earnings beat estimates and company raises guidance

Pfizer achieved positive results from its phase 3 JADE MONO-1 study using Abrocitinib to treat patients with moderate to severe atopic dermatitis.

Pfizer's Latest Data For JAK Inhibitor Drug Lines It Up To Take On Rivals

Pfizer (NYSE: PFE) unveils its next round of earnings this Tuesday, October 29. Get prepared with Benzinga's ultimate preview for Pfizer's Q3 earnings.

Pfizer's Q3 Earnings Preview

Biotech and many of the so-called Big Pharma have been duds in 2019.

News for Pfizer Stock (PFE)